STANS, Switzerland, April 5, 2021 / PRNewswire / – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or “Company”), a Swiss clinical stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare central diseases and complex nervous system disorders, announced the appointment of Silvia Panigone, Ph. .D., EMBA as Chief Operating Officer. Dr. Panigone brings to NLS more than 25 years of leadership experience in the health care industry, founded and operates ADYA Consulting, a boutique advisory firm that provides strategic counseling, access to capital, and M&A consulting services to companies in the life science sector, and serves in operational and managerials in international pharmaceutical companies and clinical research organizations.
“Silvia’s outstanding experience in product development and strategic leadership in the life science industry is a perfect fit for NLS as we pursue development of Quilience® to treat narcolepsy, and define our strategy for business development and advancement of our drug pathway,” said Alex Zwyer, Executive Director of NLS Pharmaceutics. “Its proven ability to guide emerging biotech and pharmaceutical companies from the early stages of development through a period of significant growth will be critical as we seek to drive corporate initiatives and build value within the Company. All of us at NLS give a warm welcome to Silvia. “
“I am delighted to join the NLS team and oversee the main operational activities of the Company so that we can provide patients with new treatments for rare and complex CNS disorders,” said Dr. Panigone. “NLS is focused on developing therapies intended to meet unmet medical needs, and our flagship product, Quilience, ® has the potential to be the first-line treatment for narcolepsy targeting the orexin-2 receptor, the root cause of the disorder. Given the importance of this candidate product, a top priority we are getting IND approval in the US and getting Quilience to the clinic as fast as possible. “
Prior to joining the NLS, Dr. Panigone is the managing director of ADYA Consulting Sagl, a Swiss investment boutique in the life science sector that operates globally and supports companies in corporate strategy and fundraising. He has also acted as temporary management in about one-third of ADYA’s biotech and pharmaceutical clients, and has held several Board positions in private companies, helping some to realize M&A solutions. Dr. Panigone combines a deep understanding of corporate finance as well as the drug development process and execution. Prior to ADYA, he was the former President Director Europe at I-Bankers Direct LLC, an equity funding web platform, as well as Advisor to I-Bankers Securities, Inc., a US investment banking group with more than 140 main offerings and co-managed offerings. He previously served as Fund Manager at BSI Healthcapital, a life science-focused venture capital firm, and Head of Venture Investments in the Merchant division of the Swiss-based bank, EFG International. Dr. R&D Experience Panigone’s broad range includes serving in operational and managerial positions at international level in pharmaceutical and CRO companies. At Bracco SpA, he leads international programs at both the preclinical and clinical stages with the regulatory team, intellectual property, CMC, preclinical and clinical internal experts, external providers, and KOL overseeing the development program as a Sponsor. He is also Global Project Manager at Quintiles Innovex Ltd., a leading global CRO, where he is responsible for managing a large clinical program conducted in the USA, Europe and Asia. Previously, Dr. Panigone serves as Senior Director at XoVenture, a global network of Life Science entrepreneurs and executives, Start-Up Coach for the Swiss government (Innosuisse), University Board Member Milan, and is a member of the European Narcolepsy Network (EUNN). He obtained a degree in Molecular Biology from the University of Milan, Ph.D. in Molecular Oncology at the National Cancer Institute and the Open University, London, and the Executive MBA from the Bocconi SDA School of Management, Milan.
Aabout NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a Swiss-based clinical stage biopharmaceutical company led by an experienced management team with a track record of developing and reusing candidate products to treat rare and complex central nervous system disorders. The Company’s main product candidate, Quilience® is a controlled release formulation of mazindol (mazindol CR) (mazindol CR), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, which has been used for many years to treat patients diagnosed with narcolepsy in a compassionate use program. The NLS completed a phase 2 study in the US evaluating mazindol CR in adult subjects with ADHD. This study met all primary and secondary end points and was well tolerated. Quilience has received the Orphan Drug Designation both in the US and in Europe for the treatment of narcolepsy.
Safe Harbor Statement
This press release contains the express or implied forward-looking statements pursuant to US Federal securities laws. For example, the NLS uses forward-looking statements when discussing Quilience® which could potentially be the first treatment for narcolepsy targeting the orexin-2 receptor, the root cause of the disorder, as well as when discussing its strategy and pipeline. , initiatives and building values, and potential benefits and approvals from Quilience®. These forward-looking statements and their implications are based on the current expectations of NLS management only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; The NLS may experience delays or bottlenecks in its launch and / or successful completion of its clinical trials; NLS products may not be approved by regulatory bodies, NLS technology may not be validated due to further advances and its methods may not be accepted by the scientific community; NLS may not be able to retain or attract key employees whose knowledge is essential to product development; Unexpected scientific difficulties may develop with the NLS process; The NLS product may become more expensive than anticipated; laboratory results may not translate to equally good results in real clinical settings; the results of preclinical studies may not correlate with the results of clinical trials in humans; The NLS patent may not be enough; NLS products can harm recipients; a change in the law could have a devastating effect on the NLS; inability to develop and introduce new technologies, products and applications in a timely manner; loss of market share and pressure on prices due to competition, which could cause NLS’s actual results or performance to differ materially from those intended in those forward-looking statements. Unless required by law, NLS has no obligation to publish any revisions to this forward-looking statement to reflect events or circumstances after the date of this agreement or to reflect unforeseen events. More detailed information about the risks and uncertainties affecting NLS is provided under the heading “Risk Factors” in the final prospectus of NLS, dated January 28, 2021, filed with the SEC, which is available on the SEC website, www.sec.gov.
Alex Zwyer, CEO: +41 41 618 80 00
Investor Relations Contact
David Moscowitz: +1 202-280-0888
View original content for multimedia downloads:http://www.prnewswire.com/news-releases/nls-pharmaceutics-appoints-silvia-panigone-phd-as-chief-operating-officer-301261618.html
SOURCE NLS Pharmaceutics Ltd.